Xeris Pharmaceuticals ((XERS)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Study Overview: Xeris Pharmaceuticals recently completed a Phase 2 study titled ‘A Phase 2, Multicenter, Non-Randomized, Open-Label, Single Arm, Self-controlled Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism.’ The study aimed to establish a dose conversion factor from oral levothyroxine to XP-8121, a subcutaneous injection, and evaluate its safety and tolerability in hypothyroidism patients.
Intervention/Treatment: The study tested XP-8121, a subcutaneous injection of levothyroxine sodium, intended to replace oral levothyroxine in hypothyroidism treatment, offering a potentially more convenient dosing schedule.
Study Design: This non-randomized, open-label study utilized a single-group intervention model without masking. Its primary purpose was treatment, focusing on dose conversion and safety assessment.
Study Timeline: The study began on May 15, 2023, and was completed with results submitted by June 4, 2025. The last update was recorded on July 2, 2025, marking significant milestones in the study’s progression.
Market Implications: The completion of this study could positively influence Xeris Pharmaceuticals’ stock performance by showcasing their commitment to innovative treatment options. This development may also impact investor sentiment, especially as the company competes in the hypothyroidism treatment market.
The study is now completed, with further details available on the ClinicalTrials portal.